Marksans Pharma Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/l4fxb2vypys2jwqd5p6oluig.pdf

Key Takeaways


Teva Facility Integration & Capacity Expansion

Mark Saldanha: "you will see the full potential of revenue generation only somewhere in April 24 onwards"

Margin Dynamics & Cost Structure


Backward Integration Strategy

Mark Saldanha: "that was the objective more than anything else that because when prices go up or when circumstances happen in the market manufacturers tend to exploit the situation, so we that's the reason why we wanted to backward integrate ourselves."

Market Position & Competitive Dynamics

Mark Saldanha: "Well, it's crowded and tough as always that's the nature of the beast"

Product Pipeline & R&D


Capital Allocation & Strategic Optionality

Mark Saldanha: "The branded business does give definitely lucrative bottom lines, but that is once it reaches a certain level of revenue and optimization till then you have to invest a lot of money into marketing and sales and everything. So, it's like a chicken and egg situation."

Guidance & Commitments

CommitmentSpecificsTimeline
Teva facility full revenue potentialFull potential of revenue generation from acquired unitApril 2024 onwards
Teva plant breakevenPlant reaches breakevenFirst quarter FY25
US revenue mixUS at 45-48% of total revenueBy FY25
Backward integration raw material benefitLower raw material costs from backward integrationMid to latter part of CY2024
DMF filing for backward integrationFile DMFs for backward-integrated productsBy end of current financial year
US ANDA filing cadence4-5 ANDAs per yearOngoing annual target
Europe/UK filing cadence15-20 market authorizations per yearOngoing annual target
R&D spendApproximately 2% of revenue, may go slightly higherFY25-26
Further Teva capacity investmentAdditional investment to expand capacity"Maybe after a year and a half"

Key Metrics

MetricQ2 FY24
Operating revenue₹531 cr, +17.4% YoY vs ₹452 cr
US & North America revenue₹222.3 cr, +16.8% YoY
UK & EU revenue₹48.4 cr, +10.3% YoY
Rest of World revenue₹27.3 cr
Gross margin52.4%, +174 bps YoY from 50.7%
EBITDA₹113.9 cr, +41.9% YoY and +11.7% QoQ
EBITDA margin21.4%
Profit after tax₹83.9 cr, +39.5% YoY vs ₹60.1 cr
EPS₹1.84
H1 FY24 operating revenue₹1,031.3 cr, +16.4% YoY vs ₹886 cr
H1 FY24 EBITDA margin20.9%
H1 FY24 PAT₹154.3 cr, +28.3% YoY vs ₹120.3 cr
H1 FY24 CAPEX₹119.9 cr, includes Teva facility acquisition payment
H1 FY24 free cash flow-₹29.3 cr, driven by higher CAPEX
Cash on books₹661 cr as of 30th September 2023, debt-free
R&D spend1.6% of sales in H1 FY24; FY25-26 guidance of ~2%
OTC vs RX mix (global)70:30; US OTC ~78%
US ANDA filing target4–5 per year
Europe/UK market authorization target15–20 per year
Teva facility quarterly expense~₹10 cr
Backward integration molecules revenue share~30% of total revenue
Planned additional CAPEX (next 6–12 months)₹80–100 cr
Total planned Teva facility CAPEX including acquisition~₹200 cr